Core Viewpoint - The stock of Steady Medical (300888) has experienced a decline of 2.25% as of November 14, 2025, with significant net outflows from major and retail investors, while the company shows strong financial performance in its recent quarterly report [1][2][3]. Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1% [3] - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year [3] - The third quarter alone saw a main revenue of 2.601 billion yuan, a 27.71% increase year-on-year, and a net profit of 240 million yuan, reflecting a 42.11% rise [3] - The company’s gross margin stands at 48.32%, which is higher than the industry average of 42.35% [3] Market Position - Steady Medical has a total market capitalization of 24.493 billion yuan, ranking 4th in the beauty and personal care industry [3] - The company leads the industry with a net asset value of 12.263 billion yuan, significantly above the industry average of 3.361 billion yuan [3] - The price-to-earnings ratio (P/E) is 25.1, which is lower than the industry average of 39.28, indicating a potentially undervalued stock [3] Investor Sentiment - In the last 90 days, 21 institutions have rated the stock, with 17 buy ratings and 4 hold ratings, suggesting positive sentiment among analysts [4] - The average target price set by institutions over the past 90 days is 5.479 billion yuan, indicating potential upside from the current trading price [4]

Core Insights - The stock of Steady Medical (300888) closed at 40.49 yuan on October 30, 2025, with a slight increase of 0.52% and a trading volume of 90,000 hands, resulting in a transaction value of 368 million yuan [1] Financial Performance - For the first three quarters of 2025, Steady Medical reported a main revenue of 7.897 billion yuan, a year-on-year increase of 30.1% [3] - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year, while the net profit after deducting non-recurring gains and losses was 679 million yuan, reflecting a 43.93% increase [3] - In Q3 2025, the company achieved a single-quarter main revenue of 2.601 billion yuan, a year-on-year increase of 27.71%, and a net profit of 240 million yuan, up 42.11% year-on-year [3] Market Position - Steady Medical's total market capitalization is 23.579 billion yuan, ranking 4th in the beauty and personal care industry, which has an average market cap of 10.513 billion yuan [3] - The company has a net asset of 12.263 billion yuan, ranking 1st in the industry, with a net profit of 732 million yuan, ranking 3rd [3] - The company's price-to-earnings ratio (P/E) is 24.16, which is lower than the industry average of 38.86, ranking 3rd [3] Investment Sentiment - In the last 90 days, 19 institutions have rated the stock, with 15 buy ratings and 4 hold ratings, and the average target price set by institutions is 54.09 yuan [4]

Core Viewpoint - The stock of Steady Medical (300888) has shown a decline in price and mixed capital flow trends, indicating potential volatility in investor sentiment and market performance [1][2][3]. Group 1: Stock Performance - As of October 21, 2025, Steady Medical's stock closed at 38.25 yuan, down 0.75% with a turnover rate of 0.77% and a trading volume of 44,600 shares, amounting to a total transaction value of 170 million yuan [1]. - Over the past five days, the stock has experienced a total decline of 3.14%, with the highest closing price at 39.32 yuan on October 16, 2025 [2]. Group 2: Capital Flow Analysis - On October 21, 2025, the net outflow of main funds was 896,300 yuan, accounting for 0.53% of the total transaction value, while retail investors saw a net inflow of 1,175,640 yuan, representing 6.91% of the total transaction value [1][2]. - The financing data indicates a net purchase of 4,518,200 yuan on October 21, 2025, with a total financing balance of 316 million yuan [3]. Group 3: Financial Metrics and Industry Comparison - Steady Medical's total market capitalization is 22.274 billion yuan, with a net asset value of 12.276 billion yuan, and a net profit of 492 million yuan, ranking 4th, 1st, and 3rd respectively in the beauty care industry [5]. - The company reported a gross margin of 48.33% and a net profit margin of 9.78%, both of which are above the industry averages [5]. - For the first half of 2025, the company achieved a main revenue of 5.296 billion yuan, a year-on-year increase of 31.31%, and a net profit of 492 million yuan, up 28.07% year-on-year [5]. Group 4: Institutional Ratings - In the last 90 days, 19 institutions have rated Steady Medical, with 16 buy ratings and 3 hold ratings, indicating a generally positive outlook [6]. - The average target price set by institutions over the past 90 days is 55.11 yuan, suggesting potential upside from the current trading price [6].

Core Viewpoint - The stock of Steady Medical (300888) has shown a slight increase, with significant net inflows from institutional investors, indicating positive market sentiment towards the company [1][4]. Financial Performance - As of the latest report, Steady Medical's total revenue for the first half of 2025 reached 5.296 billion yuan, a year-on-year increase of 31.31% [3] - The net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year, while the net profit excluding non-recurring items was 461 million yuan, reflecting a 40.9% increase [3] - The company's second-quarter performance showed a revenue of 2.691 billion yuan, a 26.66% increase year-on-year, and a net profit of 243 million yuan, up 20.68% [3] Market Position - Steady Medical's total market capitalization is 22.554 billion yuan, ranking 4th in the beauty and personal care industry [3] - The company has a net asset value of 12.276 billion yuan, leading the industry [3] - The price-to-earnings ratio (P/E) stands at 22.92, which is lower than the industry average of 30.51, indicating a potentially undervalued stock [3] Investment Sentiment - In the past 90 days, 19 institutions have rated the stock, with 16 buy ratings and 3 hold ratings, suggesting strong institutional confidence [4] - The average target price set by institutions for the stock is 55.11 yuan, indicating potential upside from the current price [4] Capital Flow - On October 14, 2025, the stock experienced a net inflow of 14.4665 million yuan from institutional investors, accounting for 7.86% of the total trading volume [1][2] - Retail investors showed a net outflow of 16.0052 million yuan, representing 8.69% of the total trading volume, indicating a divergence in sentiment between institutional and retail investors [1][2]

Company Overview - Steady Medical Products Co., Ltd. is located in Longhua District, Shenzhen, Guangdong Province, and was established on August 24, 2000. The company went public on September 17, 2020. Its main business involves the research, production, and sales of cotton products [1]. Financial Performance - As of September 3, Steady Medical's stock price fell by 4.23% to 39.60 CNY per share, with a trading volume of 397 million CNY and a turnover rate of 5.57%. The total market capitalization is 23.06 billion CNY. The stock has experienced a cumulative decline of 5.51% over the past three days [1]. Revenue Composition - The revenue composition of Steady Medical is as follows: consumer products account for 51.84%, medical consumables for 47.49%, and other (supplementary) products for 0.67% [1]. Fund Holdings - Minsheng Jianyin Fund has a significant holding in Steady Medical, with one of its funds, Minsheng Jianyin Value Discovery One-Year Holding Period Mixed A (010795), reducing its stake by 26,200 shares in the second quarter, now holding 416,500 shares, which represents 4.12% of the fund's net value, ranking as the seventh largest holding [2]. Fund Performance - The Minsheng Jianyin Value Discovery fund has a current size of 390 million CNY and has achieved a return of 23.22% year-to-date, ranking 3,233 out of 8,180 in its category. Over the past year, it has returned 35.22%, ranking 4,063 out of 7,967. Since inception, the fund has incurred a loss of 15.08% [2]. Fund Manager Information - The fund manager of Minsheng Jianyin Value Discovery is Deng Kaicheng, who has been in the position for 2 years and 239 days. The total asset size under his management is 485 million CNY, with the best fund return during his tenure being 36.05% and the worst being -4.47% [2].

Core Viewpoint - The stock of Steady Medical (300888) has shown a positive performance with a closing price of 41.87 yuan, reflecting a 2.25% increase on August 28, 2025, amidst varying capital flows from different investor groups [1][2]. Financial Performance - For the first half of 2025, Steady Medical reported a main revenue of 5.296 billion yuan, representing a year-on-year increase of 31.31% - The net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year - The net profit after deducting non-recurring gains and losses was 461 million yuan, marking a 40.9% increase year-on-year - In Q2 2025, the company achieved a single-quarter main revenue of 2.691 billion yuan, a 26.66% increase year-on-year, and a net profit of 243 million yuan, up 20.68% year-on-year [3]. Market Position - Steady Medical's total market capitalization stands at 24.382 billion yuan, significantly higher than the industry average of 11.443 billion yuan, ranking 4th in the industry - The company has a net asset value of 12.276 billion yuan, leading the industry with a ranking of 1st - The company's net profit of 492 million yuan ranks 3rd in the industry, while its price-to-earnings ratio (24.78) and price-to-book ratio (2.12) rank 4th and 5th respectively [3]. Investor Sentiment - Over the past 90 days, 19 institutions have rated the stock, with 16 buy ratings and 3 hold ratings - The average target price set by institutions for the stock is 55.82 yuan [4].

Core Viewpoint - The company,稳健医疗, is experiencing a decline in stock price and has a PE ratio lower than the industry average, indicating potential investment concerns despite strong revenue growth and market presence [1][2]. Company Overview - The company specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1]. - Key products include advanced wound dressings, traditional wound care products, infection control products, and a range of personal hygiene items [1]. - The company has consistently ranked among the top three exporters of medical dressings in China and has established a strong brand presence in hospitals and pharmacies [1]. Financial Performance - For Q1 2025, the company reported a revenue of 2.605 billion yuan, representing a year-on-year increase of 36.47% [2]. - The net profit for the same period was 249 million yuan, also reflecting a year-on-year growth of 36.26% [2]. - The sales gross margin stood at 48.46%, indicating a healthy profitability level [2]. Market Position - The company's current PE ratio is 38.95, which is below the industry average of 41.61 and the median of 44.57, placing it 14th in the beauty and personal care sector [2]. - The total market capitalization of the company is approximately 29.658 billion yuan [1][2]. - Recent capital flow indicates a net inflow of 12.52 million yuan on May 12, but a total outflow of 4.9493 million yuan over the past five days [1].

Group 1 - The core viewpoint of the news highlights the performance and market position of the company, Steady Medical, in the healthcare industry, particularly in the medical dressing sector [1][2]. - As of May 9, the company's stock closed at 51.45 yuan, reflecting a 3.31% increase, with a rolling price-to-earnings (PE) ratio of 39.34 times and a total market capitalization of 29.961 billion yuan [1]. - The average PE ratio for the beauty and healthcare industry is 41.70 times, with a median of 45.39 times, placing Steady Medical at the 14th position within the industry [1][3]. Group 2 - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [2]. - The company's main products include high-end wound dressings, traditional wound care products, infection control products, and various cotton-based personal care items [2]. - According to recent performance data, for the first quarter of 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up by 36.26%, with a gross profit margin of 48.46% [2].